These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23011763)

  • 21. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
    Aksoy A; Elkiran ET; Harputluoglu H; Dagli AF; Isikdogan A; Urakci Z
    J Cancer Res Ther; 2019; 15(3):550-555. PubMed ID: 31169219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
    Park Y; Kim DS; Park KH; Baek SK; Kwon SY; Shin SW; Jung KY; Kim CY; Kim YH; Lee NJ; Kim JS; Kim IS
    Onkologie; 2012; 35(11):673-82. PubMed ID: 23147544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
    Koh Y; Kim TM; Jeon YK; Kwon TK; Hah JH; Lee SH; Kim DW; Wu HG; Rhee CS; Sung MW; Kim CW; Kim KH; Heo DS
    Ann Oncol; 2009 Aug; 20(8):1414-9. PubMed ID: 19468031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
    Goyal S; Parikh RR; Green C; Schiff D; Moran MS; Yang Q; Haffty BG
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):679-84. PubMed ID: 19464815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
    Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
    Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.
    Dudás J; Schartinger VH; Romani A; Schweigl G; Kordsmeyer K; Marta PI; Url C; Kral F; Riechelmann H
    Tumour Biol; 2014 Aug; 35(8):7807-19. PubMed ID: 24817012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis.
    Xuelei M; Jingwen H; Wei D; Hongyu Z; Jing Z; Changle S; Lei L
    Oral Oncol; 2015 May; 51(5):483-92. PubMed ID: 25754170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
    Bahamon BN; Gao F; Danaee H
    Arch Pathol Lab Med; 2016 Dec; 140(12):1397-1403. PubMed ID: 27610644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
    Bai ZL; Wang YY; Zhe H; He JL; Hai P
    Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Shen C; Chen L; Fu J; Lin H
    J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.
    Dorff TB; Schuckman AK; Schwartz R; Rashad S; Bulbul A; Cai J; Pinski J; Ma Y; Danenberg K; Skinner E; Quinn DI
    Clin Genitourin Cancer; 2016 Oct; 14(5):450-456.e1. PubMed ID: 26935231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck.
    Snietura M; Jaworska M; Mlynarczyk-Liszka J; Goraj-Zajac A; Piglowski W; Lange D; Wozniak G; Nowara E; Suwinski R
    PLoS One; 2012; 7(3):e33396. PubMed ID: 22413021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
    Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
    Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
    J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
    Cubukcu E; Fatih Olmez O; Saraydaroglu O; Akcali U; Kanat O; Kurt E; Evrensel T; Manavoglu O
    Clin Transl Oncol; 2011 Nov; 13(11):826-30. PubMed ID: 22082649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological correlation of the expression of excision repair cross complementation group 1 (ERCC1) in oral cavity squamous cell carcinomas: an immunohistochemical study.
    Pankaj D; Guddattu V; Solomon MC
    Exp Oncol; 2020 Jun; 42(2):135-139. PubMed ID: 32602295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.